Przybylik-Mazurek Elwira, Kurzynska Anna, Skalniak Anna, Hubalewska-Dydejczyk Alicja
Kopernika street 17, 31-501 Krakow, Poland.
Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):103-10. doi: 10.2174/1872214809666151005123928.
Congenital adrenal hyperplasia (CAH) is one of the most common diseases transmitted in an autosomal recessive manner and is caused by mutations of enzymes which are responsible for the process of adrenal steroidogenesis. According to the impairment of enzymes involved in steroidogenesis, several types of CAH can be distinguished. The most common type is associated with mutations in the CYP21A2 gene, encoding 21-hydroxylase enzyme and has different clinical forms: Classical (in which there are two types: salt wasting and simple virilization) and non-classical, characterized by less severe symptoms and late onset. CAH is characterized by a strong correlation between the genotype and the phenotype. Mutations in the CYP21A2 gene can cause different degrees of loss of 21-hydroxylase enzyme activity which result in a wide spectrum of clinical pictures. Several methods used to diagnose CAH (such as determining steroids in serum or urine) have been known from the 70's. Modern diagnosis of CAH is based primarily on the use of genetic testing, which is the subject of numerous constantly updated patents. In this paper the most recent patents on the diagnosis of CAH were assessed.
先天性肾上腺皮质增生症(CAH)是最常见的常染色体隐性遗传疾病之一,由负责肾上腺类固醇生成过程的酶突变引起。根据参与类固醇生成的酶的损伤情况,可以区分出几种类型的CAH。最常见的类型与编码21-羟化酶的CYP21A2基因突变有关,有不同的临床形式:经典型(其中有两种类型:失盐型和单纯男性化型)和非经典型,其特点是症状较轻且发病较晚。CAH的特点是基因型和表型之间有很强的相关性。CYP21A2基因突变可导致21-羟化酶活性不同程度的丧失,从而导致广泛的临床表现。从70年代起就已知道几种用于诊断CAH的方法(如测定血清或尿液中的类固醇)。现代CAH诊断主要基于基因检测的应用,这是众多不断更新的专利的主题。本文评估了关于CAH诊断的最新专利。